(b)(4).During processing of this complaint, attempts were made to obtain complete event, patient and device information.(b)(4).The device was not returned for analysis.A review of the lot history record revealed no manufacturing nonconformities that would have contributed to this complaint.Additionally, a review of the complaint history did not indicate a lot specific quality issue.It should be noted that the xience sierra, everolimus eluting coronary stent system (eecss), instructions for use (ifu) instructs to stent the distal lesion prior to stenting the proximal lesion.Stenting in this order reduces the chance of damaging or dislodging the proximal stent.The investigation determined the reported difficulties and subsequent treatments appear to be related to the use error, as it is likely the device interacted with the previously implanted stent during advancement resulting in the reported failure to advance, ultimately causing the reported stent dislodgement during retraction of the device.There is no indication of a product quality issue with respect to the design, manufacture or labeling of the device.
|